SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum

Brain Research

Volumn 977, Issue 2, 2003, Pages 270-277

  Wardas, Jadwiga ^a   Pietraszek, Małgorzata ^a   Dziedzicka Wasylewska, Marta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine A2A receptor; Catalepsy; In situ hybridization; Parkinson's disease; Proenkephalin mRNA; Striatum

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; HALOPERIDOL; MESSENGER RNA; PROENKEPHALIN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; IN SITU HYBRIDIZATION; MALE; MOTOR SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0037831276     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02759-8     Document Type: Article

References (39)

1. 2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J. Neurochem. 58:1992;1104-1109.
2. 2A receptor antagonist. J. Neurosci. 20:2000;5848-5852.
3. 2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain. Brain Res. 953:2002;119-125.
4. Augood S.J., Emson P.C., Mitchell T.J., Boyce S., Clarke C., Crossman A.R. Cellular localization of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Brain Res. Mol. Brain Res. 6:1989;85-92.
5. Boyson S.J., McGonigle P., Molinoff P.B. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:1986;3177-3188.
6. Brown L.L., Sharp F.R. Metabolic mapping of rat striatum: somatotopic organization of sensorimotor activity. Brain Res. 686:1995;207-222.
7. 2A receptor blockade plus L-DOPA in dopamine-denervated rats. Synapse. 44:2002;166-174.
8. Chapman M.A., See R.E. Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. J. Pharmacol. Exp. Ther. 277:1996;1586-1594.
9. 2 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 98:2001;1970-1975.
10. Drew K.L., O'Conor W.T., Kehr J., Ungerstedt U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmacol. 187:1990;385-397.
11. Dziedzicka-Wasylewska M., Rogóż R. The effect of prolonged treatment with imipramine and electroconvulsive shock on the levels of endogenous enkephalins in the nucleus accumbens and the ventral tegmentum of the rat. J. Neural. Transm. Gen. Sect. 102:1995;221-228.
12. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321:1997;143-147.
13. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology. 133:1997;107-120.
14. 2 dopamine receptors in rat striatum. Mol. Brain Res. 14:1992;186-190.
15. Gerfen C.R. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 23:(Suppl.):2000;S64-S70.
16. Grimm J.W., See R.E. Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats. Neuroscience. 100:2000;507-514.
17. 2a receptors in the striatum induces catalepsy that is reversed by antagonists of N-methyl-D-aspartate receptors. Neurosci. Lett. 196:1995;205-208.
18. Herrero M.-T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luqin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
19. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine: II. Effects of 6-hydroxydopamine or colchicines microinjections into the VTA or reserpine treatment. Exp. Neurol. 113:1991;277-290.
20. 2A antagonist KW 6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162:2000;321-327.
21. 2A receptor in basal ganglia. Biosci. Biotechnol. Biochem. 65:2001;1447-1457.
22. Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J., Costentin J., Heath J.K., Vassart G., Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking A2a receptor. Nature. 388:1997;674-678.
23. 2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotoxicity Res. 3:2001;545-556.
24. Noailles P.A., Villegas M., Ledoux M., Lucas L.R., McEwen B.S., Angulo J.A. Acute treatment with the N-methyl-D-aspartate receptor antagonist MK-801: effect of concurrent administration of haloperidol or scopolamine on preproenkephalin mRNA levels of the striatum and nucleus accumbens of the rat brain. Neurosci. Lett. 202:1996;165-168.
25. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience. 100:2000;53-62.
26. Ossowska K., Karcz-Kubicha M., Wardas J., Kreżołek A., Wolfarth S. Zona incerta-lateral hypothalamus as an output structure for impulses involved in neuroleptic drug-induced catalepsy. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:1993;415-420.
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Acad. Press, San Diego.
28. 2A receptor mRNA by dopamine denervation. Eur. J. Pharmacol. 446:2002;75-82.
29. Pollack A.E., Wooten G.F. D2 dopaminergic regulation of striatal proenkephalin mRNA levels is mediated at least in part through cholinergic interneurons. Mol. Brain Res. 13:1992;35-41.
30. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18:1997;338-344.
31. 2A receptor in the striatum. Adv. Neurol. 80:1999;111-119.
32. 2A receptors in the rat central nervous system. J. Comp. Neurol. 401:1998;163-186.
33. Schiffmann S.N., Jacobs O., J Vanderhaeghen J. The striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons. An in situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
34. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 147:1999;90-95.
35. Turski L., Havemann U., Kuschinsky K. GABAergic mechanisms in mediating muscular rigidity, catalepsy and postural asymmetry in rats: differences between dorsal and ventral striatum. Brain Res. 322:1984;49-57.
36. Voorn P., Roest G., Groenewegen H.J. increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
37. 2A receptors in regulation of the muscle tone in rats. Neurosci. Lett. 276:1999;79-82.
38. 2A adenosine receptor antagonists, counteracts parkinsonian-like muscle rigidity in rats. Synapse. 41:2001;160-171.
39. 2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;389-404.